市場調查報告書
商品編碼
1465624
移植分子診斷Molecular Diagnostics for Transplant |
在預測期內,移植分子診斷的市場規模預計將以 8.91% 的複合年增長率成長。
由於氣候變遷、快速都市化和微生物演化等多種因素,傳染病正在增加。 移植患者容易受到各種感染,包括細菌、病毒、真菌和寄生蟲,因此移植前必須特別小心。 這些包括流感病毒感染、泌尿道感染、肺炎球菌肺炎、鉅細胞病毒、EB 病毒和人類皰疹病毒 6。 抗生素抗藥性的增加也是一個嚴重問題,會加劇傳染病的流行。 因此,傳染病發病率的增加透過增加對移植中進行徹底分子診斷的需求來推動市場。
北美市場在 2021 年佔最大份額。 這是由於技術的進步和慢性疾病的增加導致器官移植的增加。 研究表明,美國的腎臟、肝臟、心臟、肺、胰臟和腸道移植數量正在增加,加拿大的腎臟移植數量也在增加。
由於腎臟、心血管和呼吸系統疾病等慢性疾病的盛行率不斷上升,歐洲市場佔據第二大份額。 此外,亞太市場預計將在預測期內獲得相當大的份額。 該地區人口老化不斷加劇,越來越多的人要求進行器官移植。
本報告調查了全球移植分子診斷市場,提供了市場定義和概述,分析了影響市場成長和市場機會的因素、市場規模、各個細分市場和地區的趨勢和預測,我們編制了單獨的細分、競爭環境。
Molecular Diagnostics for Transplant Market Research Report Forecast till 2030
Molecular Diagnostics for Transplant Market is anticipated to register a CAGR of 8.91% during the review period.
Expanding pervasiveness of irresistible illnesses, rising number of transplant systems, and progressions in molecular symptomatic methods are reinforcing the market development.
There has been a rising pervasiveness of irresistible illnesses attributable to different factors, for example, environmental change, quick urbanization, microbial development, among others. Exceptional consideration should be accepted before transplantation as a transplant patient can get any kind of contamination brought about by microorganisms, infections, organisms and parasites. These incorporate flu infection contamination, urinary lot disease, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr infection, Human herpesvirus 6, among a few others. Besides, expanding antimicrobial obstruction is likewise a reason for serious concern and has been adding to the rising predominance of irresistible infection. For example, as per the Communities for Infectious prevention and Anticipation, more than 2.8 million antimicrobial-safe contaminations happen in the US every year. Subsequently, expanding commonness of irresistible sickness has driven the interest for execution of exhaustive molecular diagnostics in transplantation, in this manner, driving the market.
The Molecular Diagnostics for Transplant Market, based on product is segmented into reagents & kits, instruments, and services & software.
Based on technology the market is divided into polymerase chain reaction (PCR), sequencing, microarray, and others.
Based on end user, the market has been classified into the hospitals and transplant centers, research laboratories & academic institutes, and others.
Regional Insights
North America molecular diagnostics for transplant market represented the biggest piece of the pie in 2021, because of rising interest innovation development and expanding rates of ongoing sicknesses that lead to an expansion in organ transplants. As per research, the quantity of kidneys, liver, heart, lung, pancreas, and digestive tract transplants is expanding in the US, while the quantity of kidney transplants is expanding in Canada.
Europe molecular diagnostics for transplant market represents the second-biggest market attributable to the rising pervasiveness of constant infections, including kidney, cardiovascular sicknesses (CVD), and respiratory illnesses. Headways in molecular diagnostics have worked on the recognizable proof and comprehension of explicit quality imperfections for the suitable organ transplant in kidney, heart, and lung disappointment. CVD illnesses are impacted by variables, for example, atherosclerosis, blood clusters, diabetes, a stationary way of life, and weight, which might prompt heart disappointment.
The Asia-Pacific molecular diagnostics for transplant market is supposed to develop at a critical share from 2022 to 2030. The region's developing geriatric populace requests organ transplantation, which might change according to organ disappointment. In 2020, as per the World Financial Forum, China, India, and Japan had the most established populaces universally. Moreover, it has been assessed that by 2050, one of every four matured individuals will be living in the region.
Key Companies in the Molecular Diagnostics for Transplant Market are Thermo Fisher Scientific Inc. (US), Abbott Laboratories, Inc. (US), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), BioMerieux SA (France), Hoffmann-La Roche Ltd. (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), and Others.